Neuro Genomics Center #NGC
The NGC will apply Precision Medicine to neurodegenerative diseases, namely Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) and related disorders. They are all incurable diseases with staggering social impact, and their molecular mechanisms remain unclear.
The NGC will carry out a coordinated effort to establish Precision Medicine for neurodegenerative diseases by: i) classifying patients according to their genomic sequences associated with a group of symptoms, ii) identifying biomarkers to diagnose disease, iii) monitoring disease progression, iv) deepening understanding of disease mechanisms, and v) developing new treatments.
The NGC will study AD, PD, ALS and related disorders in an integrated fashion, since these diseases may manifest overlapping molecular and neuropathological traits. The center will strictly collaborate with Clinical Neuroscience Centers and will be interconnected with the other Human Technopole Centers, namely AFNGC, CLSC, DSC, and CNST. The NGC will also make it a priority to develop close interactions with biotechnology and pharmaceutical companies.
The Neuro Genomic Center will be organised along three main Research Lines:
The Central Genomic Facility (F1) and the Facility (F4) for common shared service for in vivo and in vitro modeling will support the activity of the research lines.
The NGC will comprise a central research facility at the Arexpo site and several collaborating laboratories inside and outside HT.
Collaborative agreements will involve IIT (Genomics, Bioinformatics, NeuroDrugMap, RNA-based Therapy, Neurodelivery), the University of Milano (Mesoscale Lab), the University of Milano-Bicocca (Biomarkers), Humanitas (Cognition and Plasticity, Neuroinflammation) M. Negri Pharmacologic Institute (Mouse Clinic) San Raffaele Hospital (Human Technologies) The C. Besta Neurologic Institute (with an associated clinical neurosciences network) will direct the Clinical Units and the construction of the Brain Bank.